INSIGHTS ON DRUG DEVELOPMENT
-
Optimize Your RNA-LNP Delivery With Ionizable Lipids
Ionizable lipids play a crucial role in optimizing LNP delivery. Discover how lipid nanoparticles revolutionize intracellular drug delivery to enhance RNA vaccines, cell therapies, protein replacement, and gene editing.
-
Integrating Phase-Appropriate Quality Standards
Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.
-
Quantification Of Semaglutide With A Reliable Analytical Method
Explore a validated LC-MS/MS method for precise Semaglutide quantification in plasma, which features enhanced sensitivity, peak definition, and reproducibility using innovative technologies.
-
Get Smoother Separations, Faster: Troubleshoot Method Development
Strong chromatography requires more than separation. Fine-tuning pH, columns, and system volume prevents poor peak shape, while modeling tools streamline optimization for reproducible results.
-
MicroCoat™ Technology DFor Taste-Masking Amodiaquine, Artesunate In Oral Antimalarial Formulations1/14/2026
Drive forward the development and adoption of taste‑masked ASAQ micropellets so children in low‑resource settings can receive life‑saving antimalarial treatment that is both effective and easy to take.
-
AustinPx Site Tour5/2/2025
Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.
-
Evaluating Carryover When Using A TOC Analyzer4/10/2026
Accurate TOC results shouldn’t depend on sample order. See how low-level measurements remain reliable even after high-TOC analysis, helping reduce false positives and streamline decisions.
-
API In Capsule Vs. The Lost Art Of Formulation Development11/5/2025
API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.
-
Lonza Advanced Synthesis Capabilities Update February 2026: AI Drug Development3/2/2026
Learn how our scientists accurately predict and identify the most stable cocrystal forms by leveraging advanced machine learning models, enhancing efficiency and reducing development risks.
DRUG DEVELOPMENT SOLUTIONS
-
MabSelect™ VL affinity resin uses a protein L ligand with strong affinity for the variable region of a human antibody’s kappa light chain. The resin offers high productivity and robust processes for affinity capture of bispecific antibodies and antibody fragments containing the kappa light chain and offers a good capture alternative for antibody variants that does not bind to protein A.
-
The ACQUITY Premier Solution enables your lab to make informed decisions and reduce risk with stronger analytical capabilities to detect more of your sample components from the very beginning.
-
Learn how peptide‑synthesis platforms, early impurity control, and optimized downstream methods boost scalability, stability, and development speed from early design to late‑stage readiness.
-
MaxPeak™ Premier Columns utilize MaxPeak High Performance Surfaces that are designed to increase analyte recovery, sensitivity, and reproducibility by minimizing analyte/surface interactions that can lead to sample losses.
-
Accurate, high-sensitivity quantitation of residual host cell DNA becomes faster and more consistent with integrated qPCR, automated prep, and broad assay coverage—helping streamline workflows.